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INTRODUCTION
Incidence rate of IBD is stabilizing in some developed coun-
tries;1-4 however, the incidence rate is increasing in developing 
countries such as Asia and Eastern Europe.5-7 Recent nation-
wide report in Iran showed the increasing trend in incidence 
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Background/Aims: A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. 
The Iranian Registry of Crohn’s and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods 
of data collection, and aims of IRCC in this paper. Methods: IRCC is a multicenter prospective registry, which is established with 
collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined 
according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 
IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach’s α. Results: All sections 
of questionnaire had Cronbach’s α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 
years (standard deviation = 12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education 
and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), and 13 (2.3%) of participants were smok-
ers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common 
medication was 5-aminosalicylate (94.39%). Conclusions: To the best of our knowledge, IRCC is the first national IBD registry 
in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve 
the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran. 
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and prevalence of both UC and CD.8 The rising incidence and 
prevalence of IBD made an essence to investigate the risk fac-
tors and possible etiologies of this disease and necessitates 
further studies for better understanding of natural history, 
phenotype, treatment response, complication, and survival of 
the patients who suffer from IBD. Establishing a prospective 
IBD registry is one the best way to answer these questions.9 
Iranian ministry of health have recently launched a program 
of supporting disease registries.10 Following this initiative, we 
established a multicenter national IBD registry named “Irani-
an Registry of Crohn’s and Colitis (IRCC).” Each disease regis-
try has its own limitation and strength and thereby could not 
answer all clinical or epidemiological questions related to that 
disease.11 Introducing the study design, data collection, and 
aims of IRCC enlighten the strengths and limitations and may 
help researchers to better interpret the results of this nation-
wide study in future.
The aim of IRCC is to study clinical phenotype, safety of treat-
ment, pattern of care across country, risk of colorectal cancer, 
prognostic factors, complication, survival, incidence and prev-
alence of IBD in Iran. Another objective is to set up a blood 
and stool biobank of IBD patients which its protocol will be 
published in near future. In this report we described the study 
protocol, process of IRCC implementation and assessment of 
its feasibility in Iran.
METHODS
1. Registry Setting and Organization
IRCC is a multicenter prospective registry enrolling adult pa-
tients diagnosed as IBD. Patients are managed according to 
their routine care and no intervention from the registry team 
would be imposed. The registry comprises of referral centers 
of IBD located in the capital and all provincial centers of Iran.
IRCC was organized under the guidance of steering com-
mittee of 7 senior gastroenterologists from major gastroenter-
ology departments and research centers of Iran. These mem-
bers were selected based on their expertise and interest in re-
search and care of IBD patients. One member of steering com-
mittee was selected as principal investigator and director of 
registry in order to supervise the executive team (Fig. 1) which 
consists of an executive manager, 2 registrars, a nurse as pa-
tient educator, an information technology (IT) technician and 
2 researchers. Gastroenterologists who shared their cases with 
registry were considered as IRCC collaborators. The executive 
team had a time chart and objectives for each year which were 
followed in weekly regular meeting. An authorship guideline 
was approved by steering committee after receiving comments 
from all collaborators. The study was approved in Ethic Com-
mittee of Digestive Disease Research Institute of Tehran Uni-
versity of Medical Sciences. IRCC was funded by deputy of re-
search of the Ministry of Health and Medical Education and 
was strongly supported for all logistics by the Iranian Associa-
tion of Gastroenterology and Hepatology (IAGH).
In Iran, all IBD patients were served at provincial center rath-
er than villages or small cities. IRCC has at least 1 center in 
each province. From different provinces, 449 gastroenterolo-
gists who visit IBD patients in public or private clinics have ac-
cepted to collaborate with IRCC. According to report from 
IAGH 517 gastroenterologists are presently working in Iran. 
Therefore, IRCC covers 87% of all GI centers around the coun-
try (Fig. 2, Supplementary Table 1). However, the exact partici-
pation rate could be calculated after finishing the registry pro-
cess. Of different provinces of Iran, the most modernized and 
industrialized are Tehran, Razavi Khorasan, Fars, Isfahan, Ma-
zandaran, East Azerbaijan, and Gilan in which the majority of 
gastroenterologists work and most of IBD patient were treated 
there. Distribution of gastroenterologists in Iran was shown in 
Supplementary Table 1 and Supplementary Fig. 1. 
2. Study Population 
Study population consisted of adult who were diagnosed as 
IBD by gastroenterologists in collaborating centers across the 
country. The exclusion criteria were set for patients who aged 
less than 18 years and for those who were unable or unwilling 
to provide informed consent. Patients with un-confirmed di-
agnosis also were excluded. 
Fig. 1. The Iranian Registry of Crohn’s and Colitis organization. IT, 
information technology.
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3. Disease Definition 
IBD is defined as combination of clinical, radiological, colono-
scopic, and pathologic and classified to UC and CD according 
to international IBD guideline12 as below. This uniform criteri-
on was attached as appendix to IRCC questionnaire and sent 
to all collaborating provincial centers.
1) Clinical
History of rectal bleeding or bloody mucus diarrhea, abdomi-
nal pain, vomiting, weight loss, fistulas, and fever. Finding such 
as pallor, cachexia, mild abdominal tenderness, perianal in-
volvement (fissure, fistula, and abscess) in physical examina-
tion. Predominantly bloody diarrhea was in favor of UC. Ab-
dominal pain, malnutrition, and perianal lesions were in favor 
of CD. 
2) Laboratory Tests
Evidence of anemia and thrombocytosis in complete blood 
count, elevated ESR or CRP, negative stool exam and culture 
to rule out bacterial or parasitic infection and elevated level of 
fecal calprotectin. Anti-neutrophil cytoplasmic antibody and 
Anti-Saccharomyces cerevisiae antibody were in favor of UC 
and CD respectively.
3) Colonoscopic
Evidence of ulcers, aphthous lesions, inflammation, bleeding, 
stenosis, pseudo-polyps in colon. Capsule endoscopy and en-
teroscopy were used in cases of small bowel involvement when 
other modalities have been negative and IBD was strongly 
suspected. Continuous superficial colonic mucosal lesions, 
and spontaneous bleeding were in favor of UC. Patchy trans-
mural asymmetric lesions mainly involving ileum and right-
sided colon, deep fissures, cobblestone appearance, and lon-
gitudinal ulcers were in favor of CD.
4) Imaging
CT or magnetic resonance enterography were used to assess 
involvement of small bowel. Findings such as full thickness in-
flammation, wall thickening of small bowel, strictures and fis-
tula tract were in favor of CD. Also pelvic MRI used for evalu-
ating perianal disease if suspected. 
5) Pathologic
Biopsies were routinely obtained during endoscopy. Report of 
crypt abscess destruction and non-caseating granuloma were 
evidence of UC and CD disease respectively. 
4. Disease Activity
Disease activity were assessed by international patient-cen-
tered instruments which were mostly based on clinical symp-
toms and were validated and correlated with colonoscopic, 
laboratory, and imaging findings. IBD-control-8 questionnaire 
for checking patients’ recent symptoms (score more than 13 
indicates inactive disease)13 and Manitoba IBD index for check-
ing disease control in 6 months before interview (score more 
than 4 indicates inactive disease) were used in IRCC question-
naire.14
5. Drug Availability
More than 95% of Iranians are covered by national health in-
surance and cost of almost all IBD-related drugs including bio-
logics are supported. Furthermore, patients have access to all 
type of treatments including anti-TNF drugs. Therefore, the 
pattern of IBD treatment in Iran would not be affected by drug 
availability.
6. Questionnaire
We define our minimum data set for IRCC according to an in-
ternational consensus on standard set of patient-centered out-
come for IBD which has been reported recently.15 The ques-
Fig. 2. Participation rate of gastroenterologists in different prov-
inces of Iran with Iranian Registry of Crohn’s and Colitis study.
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tionnaire has been developed and agreed following an ex-
haustive consultation process with technical supervisors and 
steering committee. And contains following sections: demo-
graphics, habitual, comorbidities, disease activity, quality of 
life, healthcare utilization, treatment complications, survival 
and disease control (Table 1, Supplementary Material 1). Stan-
dard queries were included in the questionnaire to interview 
patients on education level,16 past medical history,17 symptoms 
of IBD in last 2 weeks13 and disease control in last 6 months.14 
Questions containing information on disease subtype, extent 
of intestinal involvement, clinical phenotype, and IBD-related 
surgery were specified to be answered by physician (clinician-
reported). Since opium and hookah use is common in Iran, 
related questions were added to questionnaire in order to eval-
uate their association with IBD.
7. Enrollment
In order to enroll cases, a web-based software and website18 
were designed by our IT technician. Collection of data would 
be performed in different ways after obtaining the consent 
from patients (Fig. 3). Any gastroenterologist could register 
his/her IBD patient information in the web-based software 
primarily and then the registrar from IRCC office calls the pa-
tient and fills the rest of questions. Patient enters his/her con-
tact information directly into the web-based software. Regis-
trar then calls the patient and fills the rest of questions. Any 
IRCC collaborator could fill a paper-based questionnaire and 
then sends it to the IRCC office by post to be entered to the 
database by registrars. Patient can directly refer to IRCC office 
and provides the necessary information to the registrar. For 
confidentiality of data, our software generates an identifica-
tion code for each case which would be used for exporting an-
onymized data. 
8. Follow-up
After enrolling IBD patients, annual telephone call will be 
made to each patient and data about treatment complications, 
symptoms and quality of life, admission and emergency de-
partment visits, and disease control will be collected. In addi-
tion, all IRCC collaborators are available to help and complete 
the follow up data. Any outcome such as, IBD flare-up, IBD-re-
lated surgery and disability and death will be recorded and re-
lated documents will be reviewed accordingly.
9. Pilot Study
To evaluate the feasibility of our project, we designed a pilot 
Table 1. Variables Included in Questionnaire of the Iranian Regis-
try of Crohn’s and Colitis 
Contact information
National ID code
Demographics 
   Gender
   Age
   Ethnicity
   Education
   Place of birth and residence
   Marital status
Past medical disease (and age of disease onset)
   Self-comorbidity questionnaire
   History of appendectomy
   History of HBV, HIV, and tuberculosis
Family history of IBD
   First degree
   Second degree
Habitual
   Cigarette (amount and duration of use)
   Hookah (amount and duration of use)
   Opium (amount, duration, type, and route of use)
IBD-related medications (type and duration of use)
Symptoms and quality of life 
   IBD-control questionnaire
   Body weight
   Presence of fistula
Treatment complication 
   Steroid use and its duration
Healthcare utilization
   Admission to hospital
   Emergency department visits
Survival and disease control
   Manitoba IBD index
   Colon cancer
IBD clinical information (clinician-reported)
   Diagnosis date
   Disease subtype 
   Disease extension (Montreal classification)
   Disease phenotype (Montreal classification)
   Extraintestinal manifestation
   IBD-related surgery
study on 553 IBD patients whom their contact information 
was available. The majority of studied subjects (n = 529, 95%) 
were registered primarily by their gastroenterologist with pa-
per-based questionnaire and then the registrar from IRCC of-
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fice called them for interview. The minority of patients (n = 12, 
2%) attended the IRCC office directly and 17 patients (3%) 
were registered into the website by their physician. At the end 
of pilot study, all IRCC collaborators were invited and the study 
design, data collection, questionnaire and results of pilot study 
were presented. All comments on study protocol were consid-
ered and the final version of questionnaire was developed. 
The quality control protocol for process of data collection and 
data accuracy was defined according to the caveats in pilot 
study.
10. Quality Control of Registry Process
Case enrollment was based on diagnosis of IRCC collabora-
tors who were committed to use standard disease definition 
and protocol. Quality of data collection was monitored by ran-
dom recording and checking of interviews performed by reg-
istrars. Moreover, our designed software has some validation 
rules which does not let wrong data to be registered and it has 
monitoring dashboard for executive manager to follow rate of 
response and missing data. All registrars were trained in the 
IRCC office.
11. Quality Control of Data
We used standard minimum data set of outcomes related to 
IBD,15 to guarantee that our data would be comparable to oth-
er IBD registries throughout the world. As IRCC collaborators 
were committed to share the information of eligible cases, we 
can assume that selection bias is minimal. We expect the com-
pleteness of collected data by using the IRCC software which 
has obligatory fields for necessary questions. There is also a 
protocol for random checking of questions answered by phy-
sician in order to check the construct validity of clinician-re-
ported questions. Annual report will be released and sent to 
registry office at deputy of research in ministry of health and 
all IRCC collaborators.
12. Statistics
Face validity of our questionnaire was checked by multiple 
sessions of expert panel for reviewing the questions and by re-
ceiving feedbacks from registrars during and after pilot study. 
The reliability of each section was evaluated by Cronbach’s α. 
We used chi-square test for comparing categorical variables 
and ANOVA with Bonferroni post hoc test for comparing con-
tinuous variables. P-value less than 0.05 considered signifi-
cant. Analysis carried out using STATA software, version 11 
(StataCorp LLC, College Station, TX, USA).
RESULTS
The mean age of participants was 38.60 years (SD, 12.86) with 
312 of them were male (56.42%). About half of subjects (n = 303, 
54.78%) had university education. Fars ethnicity comprise 
64.74% of our enrolled subjects (n = 358). Majority of regis-
tered subjects had UC (n = 378, 68.35%). We observed that 68 
of patients (12.30%) were smoker and 44 subjects (7.96%) were 
hookah users and only 13 patients (2.35%) reported opium 
Fig. 3. Data collection pattern in Iranian Registry of Crohn’s and Colitis (IRCC).
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Characteristic Value
Ethnicity 
   Fars 358 (64.74)
   Turk  90 (16.27)
   Lor 33 (5.97)
   Kurd 35 (6.33)
   Arab  7 (1.27)
   Other 30 (5.42)
Family history (1st degree)
   UC 50 (9.04)
   CD 15 (2.71)
   Both 65 (11.75)
Family history (2nd degree)
   UC 29 (5.24)
   CD  9 (1.62)
   Both 38 (6.87)
Disease activity during 2 weeks before enrollmenta
   Quiescent 289 (52.26)
   Active 264 (47.74)
Disease activity during 6 months before enrollmentb
   Quiescent 341 (61.66)
   Active 212 (38.34)
Age at diagnosis (yr)
   UC 31.36±12.16
   CD 27.92±11.32
   Both 30.43±11.98
Values are presented as number (%) or mean±SD.
aAccording to IBD-control-8 questionnaire.
bAccording to Manitoba IBD index. 
Table 2. ContinuedTable 2. Characteristics of Pilot Study of the Iranian Registry of 
Crohn’s and Colitis 
Characteristic Value
Sex
   Male 312 (56.42)
   Female 241 (43.58)
Age group (yr)  
   0–19       21 (3.80)
   20–29      106 (19.17)
   30–39  206 (37.25)
   40–49 120 (21.70)
   50–59    61 (11.03)
   60–69 27 (4.88)
   ≥70 12 (2.17)
Education 
   Illiterate   6 (1.08)
   Primary school   20 (3.62)
   Middle school   58 (10.49)
   High school 166 (30.02)
   Associate degree 49 (8.86)
   Bachelor 170 (30.74)
   Master   65 (11.75)
   Doctoral 19 (3.44)
Depression
   No 500 (90.42)
   Yes 53 (9.58)
Appendectomy
   No 495 (89.51)
   Yes    58 (10.49)
Smoking 
   Never 485 (87.7)
   Current user  36 (6.51)
   Past user  32 (5.79)
Age (yr)
   UC 39.51±13.25
   CD 36.10±11.78
   Both 38.58±12.87
Hookah
   Never 509 (92.04)
   Current user 32 (5.79)
   Past user 12 (2.17)
Opium
   Never 540 (97.65)
   Current user  9 (1.63)
   Past user  4 (0.72)
(Continued to the next)
consumption. Fifty-eight patients (10.48%) had history of ap-
pendectomy of which 30 cases were before diagnosis of IBD. 
Family history were positive in 65 subjects (11.75%) for first 
degree (50 relatives had UC) and 38 (6.87%) for second-de-
gree relatives (29 relatives had UC). The age at diagnosis for 
UC and CD were 31.36 (SD, 12.16) and 27.92 (SD, 11.32) years 
respectively (P = 0.00). Disease duration were similar in both 
subgroups of UC and CD (8.40 ± 7.26 and 8.18 ± 7.18 years, 
P = 0.91). Most of patients (n = 341, 61.66%) had quiescent dis-
ease in 2 weeks before enrollment and 289 patients (52.22%) 
had IBD in remission during the last 6 months (Table 2). 5-Ami-
nosalicylate (5-ASA) and immunomodulator (azathioprine or 
6-mercaptopurine or methotrexate) were currently used by 
67.81% and 43.58% of participants, respectively (Table 3, Fig. 
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Table 3. Pattern of IBD Treatment in Pilot Study of the Iranian Reg-
istry of Crohn’s and Colitis 
UC CD IBD unclassified
Prednisolone
   Never 135 (35.71) 53 (32.72)   8 (61.54)
   Currently using  42 (11.11) 22 (13.58) 1 (7.69)
   Previously using 201 (53.17) 87 (53.70)   4 (30.77)
Immunomodulator
   Never 159 (42.06) 32 (19.75) 8 (61.54)
   Currently using 150 (39.68) 88 (54.32) 3 (23.08)
   Previously using  69 (18.25) 42 (25.93) 2 (15.38)
5-ASA
   Never  9 (2.38) 19 (11.73) 3 (23.08)
   Currently using 301 (79.63) 70 (43.21) 4 (30.77)
   Previously using   68 (17.99) 73 (45.06) 6 (46.15)
Anti-TNF 
   Never 233 (61.64) 47 (29.01) 10 (76.92)
   Currently using   88 (23.28) 92 (56.79)  2 (15.38)
   Previously using 57 (15.08) 23 (14.20) 1 (7.69)
Duration of use (yr)
   Prednisolone 2.63±4.40 2.61±3.35 2.37±3.24
   Immunomodulator 5.21±5.81 5.61±5.82 2.90±3.01
   5-ASA 7.09±7.22 5.01±4.90 4.79±4.64
   Anti-TNF 1.91±3.08 2.12±2.42 2.50±0.50
Values are presented as number (%) or mean±SD.
5-ASA, 5-aminosalicylate.
Table 4. Cronbach’s α of Different Sections of the Questionnaire 
in the Iranian Registry of Crohn’s and Colitis 
Section of questionnaire Cronbach’s α
Past medical history 0.79
Habitual 
   Cigarette 0.76
   Hookah 0.84
   Opium 0.63
Treatment 0.76
Symptoms and quality of life 0.82
Healthcare use and treatment complication 0.63
Survival and disease control 0.68
4). The reliability of each section of questionnaire was checked 
and all sections had Cronbach’s α> 0.6 (Table 4). 
Compared to patients with UC, those with CD were treated 
more frequently with immunomodulator (azathioprine or 6- 
mercaptopurine or methotrexate) (38.36% vs. 70.99%, P < 0.001) 
or anti-TNF (adalimumab or infliximab) (57.94% vs. 80.25%, 
P < 0.001). There was no significant difference in disease activ-
ity score between patients whom were treated with adalim-
umab compared to those consumed infliximab (P = 0.52). 
DISCUSSION
In this paper, we introduced the design and implementation 
of IBD registry in Iran named “IRCC.” Although there were few 
IBD registries at provincial level in Iran,19,20 to best of our knowl-
edge, this is the first nation-wide registry running in Middle 
East. We have assessed the feasibility of our study and face va-
Fig. 4. (A, B) The percentage of previous or current drug use for 
treatment of UC and CD in pilot study of the Iranian Registry of 
Crohn’s and Colitis. 5-ASA, 5-aminosalicylate.
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lidity and internal reliability of designed questionnaire by per-
forming a pilot study on 553 subjects. 
Although registry is a prospective observational study and 
patients are not randomly assigned to specific treatment, its 
result is as powerful as randomized controlled trials (RCT) or 
cohort studies, because patients are followed in their real-world 
life and are not excluded due to different study criteria. More-
over, the follow-up duration is always longer than RCTs. These 
advantages could help investigators to more efficiently evalu-
ate the natural course of disease and obtain more accurate 
date regarding treatment response and disease survival.21 
Similar to IRCC, multicenter registries are held in other part 
of the world. For example, SHARE registry in the United States 
is cooperation of 7 referral IBD centers focused mostly on bio-
medical researches and treatment of IBD.22 There are also mul-
ticenter IBD registries in Europe such as Austrian IBD center 
cohort which is comprised of 14 tertiary centers and aimed to 
study on disease phenotype and activity and treatment of IBD.23 
In Asia, there are 2 multihospital registries held in china and 1 
in Hong Kong which epidemiologic data from these registries 
were reported.24-26 Also there is an ongoing multicenter na-
tion-wide IBD registry in Korea.27 Although IRCC is a multi-
center IBD registry at present time, but we have planned to 
expand it by including all GI centers around the country. This 
task is more achievable with establishment of ongoing elec-
tronic medical record system in Iran. Because we would be 
able to use these records by IRCC software similar to other 
registries such as IBD UK registry28 or IBD registry at Western 
Pennsylvania.29 
Another very important initiative is the International Inflam-
matory Bowel Disease Genetics Consortium which is a net-
work of world researchers focusing mainly on the genetics of 
IBD. It has undertaken a number of large-scale genome-wide 
association studies of CD and UC, and have been able to iden-
tified more than 200 IBD risk loci with majority of these loci 
are shared across diverse ancestry groups, including Iranian.30 
By setting up bio-bank of IBD patient in Iran further studies on 
IBD genetics will be possible. Also collecting blood samples 
will be useful for study on new biomarkers for diagnosis and 
monitoring IBD and colleting stool samples will help to study 
the role of microbiota in IBD etiology and disease activity.
There are several strengths in this study including a prospec-
tive design, using a validated and reliable questionnaire based 
on accepted international minimum data set,15 a well-designed 
software and website, flexible options to enroll IBD cases, and 
registering patients with their unique national ID which will 
allow data linkage to other national studies such as cancer reg-
istry and cause of death registry. There are also some limitations 
such as absence of link to patients’ detail medical records at 
present time and before establishment of national electrical 
medical record in Iran.
In conclusion IRCC could become a reliable infrastructure 
for national and international research on IBD and at the same 
time improve the care of IBD patients and provide national in-
formation for policy makers to better plan for controlling IBD 
in Iran.
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Supplementary Fig. 1. Percentage of gastroenterologists work in different provinces of Iran.
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Supplementary Table 1. Distribution of Gastroenterologists in Iran and Participation Rate of Gastroenterologists of Different Provinces 
with IRCC Study
Province No. of gastroenterologist by IRCC list
No. of gastroenterologist 
by IAGH list
Participation  
rate
Percent of 
gastroenterologist
Alborz 2 9 22.2 1.74
Ardabil 6 6 100 1.16
Azarbaijan East 15 19 78.9 3.68
Azarbaijan West 8 9 88.9 1.74
Bakhtiyari 2 2 100 0.39
Bushehr 2 2 100 0.39
Fars 30 30 100 5.80
Gilan 14 19 73.7 3.68
Golistan 6 6 100 1.16
Hamedan 3 5 60.0 0.97
Hormuzgan 4 4 100 0.77
Ilam 3 4 75.0 0.77
Isfahan 26 36 72.2 6.96
Kerman 8 8 100 1.55
Kermanshah 5 6 83.3 1.16
Khurasan North 1 1 100 0.19
Khurasan Razavi 34 42 80.9 8.12
Khurasan South 1 1 100 0.19
Khuzistan 11 15 73.3 2.90
Kohgiluya 2 2 100 0.39
Kurdistan 2 2 100 0.39
Luristan 4 6 66.7 1.16
Markazi 3 3 100 0.58
Mazandaran 18 30 60.0 5.80
Qazvin 6 6 100 1.16
Qom 5 5 100 0.97
Semnan 2 2 100 0.39
Sistan & Baluchistan 2 3 66.7 0.58
Tehran 215 219 98.2 42.36
Yazd 7 11 63.6 2.13
Zanjan 2 4 50.0 0.77
Total 449 517 86.8 100
IRCC, Iranian Registry of Crohn’s and Colitis; IAGH, Iranian Association of Gastroenterology and Hepatology. 
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Supplementary Material 1. IRCC enrollment questionnaire.
 
 
 
“In the name of God” 
IRCC enrollment questionnaire 
Patient‐reported questions: 
Patient Demographic data  
1. Date of filling questionnaire:   
2. First Name:      
3. Last Name: 
4. National code: 
5. Gender:   1) Male   2) Female  
6. Marital status: 1) Single    2) Married 
7. Landline Phone:   
8.  Mobile Phone: 
9. Birth Date:  
10. Birth province:   
11. Birth city: 
12.  Living province:   
13. Living city: 
14. Education:  0) illiterate 1) Primary school   2) Middle school 3) High school 4) Associate degree  
5) Bachelor 6) Master 7) Doctoral 
15.  Ethnicity:   1) Fars    2) Turk    3) Lur   4) Kord     6) Arab    7) Turkman 8) Other  
16.  Twin:     0) No           1) Yes     
17. Twin type: 1) Homozygote    2) Hetrozygote              
18.  Your doctor name:        
Past medical History  
19. Did you have heart disease? Y/N  
20. Did you take medication for it?  Y/N   
21. Did it limit your activity? Y/N 
22. At what age did you get heart disease? 
23. Did you have hypertension? Y/N 
24. Did you take medication for it?  Y/N   
25. Did it limit your activity? Y/N 
26. At what age did you get hypertension? 
27. Did you have lung disease? Y/N    
28. Did you take medication for it?  Y/N   
29. Did it limit your activity? Y/N 
30. At what age did you get lung disease? 
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31. Did you have diabetes? Y/N    
32. Did you take medication for it?  Y/N 
33. Did it limit your activity? Y/N 
34. At what age did you get diabetes? 
35. Did you have gastric ulcer? Y/N    
36. Did you take medication for it?  Y/N  
37. Did it limit your activity? Y/N 
38. At what age did you get gastric ulcer? 
39. Did you have kidney disease? Y/N    
40. Did you take medication for it?  Y/N   
41. Did it limit your activity? Y/N 
42. At what age did you get kidney disease? 
43. Did you have liver disease? Y/N    
44. Did you take medication for it?  Y/N   
45. Did it limit activity? Y/N 
46. At what age did you get liver disease? 
47.  Did you have anemia or any other blood disease? Y/N    
48.  Did you take medication for it?  Y/N   
49. Did it limit your activity? Y/N 
50. At what age did you get anemia or any other blood disease? 
51. Did you had cancer? Y/N    
52.  Did you take medication for it?  Y/N   
53. Did it limit your activity? Y/N 
54. At what age did you get cancer? 
55. Did you have depression? Y/N    
56.  Did you take medication for it?  Y/N   
57. Did it limit your activity? Y/N 
58. At what age did you get depression? 
59. Did you have back pain? Y/N    
60. Did you take medication for it?  Y/N   
61. Did it limit your activity? Y/N 
62. At what age did you get back pain? 
63. Did you have history of previous TB? Y/N 
64. At what age did you get TB? 
65. Did you have history of previous HBV? Y/N 
66. At what age did you get HBV? 
67. Did you have history of previous HIV? Y/N 
68. At what age did you get HIV? 
69. Did you have history of Appendectomy?  Y/N 
70. At what age did you appendectomy? 
Social History  
71. Do you smoke? 1) Never used   2) Currently using     3) Previously using    
72. If currently or previously using, how many packet did you use per day? 
73. If currently or previously using, at what age did you start smoking? 
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74. If previously using, at what age did you stop smoking? 
75. Have you ever used hookah? 1) Never used   2) Currently using     3) Previously using    
76. If currently or previously using, how many days per week did you use hookah? 
77. If currently or previously using, at what age did you start hookah use? 
78. If currently or previously using, at what age did you stop hookah use? 
79. Have you ever used opium?  
1) Never used   2) Currently using     3) Previously using    
80. If currently or previously using, how many days per week did you use opium? 
81. If currently or previously using, at what age did you start opium use?  
82. If previously used, at what age did you stop opium use? 
83. If currently or previously using, how many nokhod per day: 
84. Type of used opium:  1) Teriak     2) Shireh    3) Sukhteh 
85. Rout of administration:  1) Oral     2) Inhaled     3) Both 
Family History 
86. Is there history of IBD in your family members: Y/N 
87. If yes, which family member: 1) father 2) mother 3) brother   4) sister    7) son   8) daughter  
 9) second degree 
88. If yes, what was the type: 1) UC   2) CD  3) Not known which subtype 
Symptoms and Signs, function and quality of life  
89. Do you believe that your IBD has been well controlled in the past 2 weeks?    
2) Yes   0) No   1) Not sure 
90. Do you believe that your current treatment is useful in controlling your IBD?  
2) Yes   0) No   1) Not sure 
91. Over the past 2 weeks, have your bowel symptoms been getting worse, getting better or not 
changed?     2) Better   1) No change   0) Worse 
In the past 2 weeks, did you: 
92. Miss any planned activities because of IBD? 0) Yes   2) No    1) Not sure 
93. Wake up at night because of symptoms of IBD? 0) Yes   2) No    1) Not sure 
94. Suffer from significant pain or discomfort? 0) Yes   2) No    1) Not sure 
95. Often feel lacking in energy? 0) Yes  2) No    1) Not sure 
96. Feel anxious or depressed because of your IBD? 0) Yes   2) No    1) Not sure 
97. Think you needed a change to your treatment? 0) Yes   2) No    1) Not sure 
 
98. Weight (in kilogram):    
99. Did you have fistula? 1) No   2) Yes   9) N/A 
 
Treatment Data   
100.  Have you ever used prednisolone for IBD treatment?  
1) Never used 2) Currently using 3) Previously using   
101. When did you start prednisolone?  
102. When did you finish prednisolone?  
103. Who stop the treatment? 1) Patient   2) Physician 
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104. If your physician stopped the treatment, what was the reason?  
1) No response 2) Non‐compliance 3) Recovery 4) Drug reaction 9) N/A 
105. Have you ever used immunomodulator for IBD treatment?  
1) Never used  2) Currently using     3)Previously using    
106. What type of immunomodulator did you use? 
1) Azathioprine    2) 6‐Mercaptopurin    3) Methotrexate 
107.  When did you start immunomodulator?  
108. When did you finish immunomodulator? 
109. Who did stop the treatment? 1)Patient   2) Physician 
110. If your physician stopped the treatment, what was the reason? 
 1) No response 2) Non‐compliance 3) Recovery 4) Drug reaction 9) N/A 
111. Have you ever used 5‐ASA for IBD treatment? 
1) Never used  2) Currently using     3)Previously using    
112. What type of 5‐ASA did you use?  1) Sulfasalazine 2) Mesalazine   
113. When did you start 5‐ASA?  
114. When did you finish 5‐ASA? 
115. Who did stop the treatment? 1)Patient   2)Physician 
116. If your physician stopped the treatment what was the reason? 
1) No response 2) Non‐compliance 3) Recovery 4) Drug reaction 9) N/A 
117.  Have you ever used anti‐TNF for IBD treatment? 
1) Never used   2) Currently using     3) Previously using    
118. What type of anti‐TNF did you use? 1) Infliximab   2) Adalimumab    
119.  When did you start anti‐TNF? 
120.  When did you finish anti‐TNF? 
121. Who did stop the treatment? 1) Patient   2) Physician 
122. If your physician stopped the treatment what was the reason?  
1) No response 2) Non‐compliance 3) Recovery 4) Drug reaction 9) N/A 
Healthcare utilization & Treatment complication 
123. What was the total number of emergency room visits in past 12 months? 
124. How many days was the IBD‐related admissions in past 12 months? 
125. Did you use steroid in previous 12 months ago? Y/N 
126. Was the duration of steroid use more than 3 months? Y/N 
127. Was there any admission after 3 months of starting treatment? Y/N  
 
Survival and Disease control 
128.  Was your IBD in remission in last 6 months? 
In the last 6 months, my disease has been 
0 = Constantly active, giving me symptoms every day 
1 = Often active, giving me symptoms most days 
2 = Sometimes active, giving me symptoms on some days [for instance 1–2 days/week] 
3 = Occasionally active, giving me symptoms 1–2 days/month 
4 = Rarely active, giving me symptoms on a few days in the past 6 months 
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5 = I was well in the past 6 months: what I consider a remission or absence of symptoms 
129. Did you have colorectal cancer after suffering from IBD? Y/N  
130. What was the diagnosis date of colorectal cancer?  
 
Clinician‐reported questions 
General clinical Data  
1. Date of Diagnosis:    
2. Final Diagnosis:  1) UC   2) CD  3) IBD unclassified   
3.  If UC what is disease extent: 1) Proctitis   2) Left sided colitis   3) Pancolitis   9) N/A 
4. If Crohn’s what is disease location: 1) Ileal   2) Colonic   3) Ileocolonic   4) Isolated upper GI  9) N/A 
5. If Crohn’s what is disease behavior: 1) Non‐fistulizing    2) Fistulizing     3) Stricturing   9) N/A 
6. Are there any extra‐intestinal manifestations? 
1)Primary sclerosing cholangitis   2) Autoimmune hepatitis 3) Gallbladder stone   4) Uveitis   5) 
Erythema nodosum   6) Pyoderma gangrenous 7) Peripheral arthritis 8) Ankylosing spondylitis   
9) N/A 
 
Surgery data 
7. Did you have surgery due to IBD disease? Y/N 
8.  If UC, what type of surgery have you done? 
 1) Proctocolectomy with ileal pouch‐anal anastomosis 2) Total abdominal colectomy with 
ileorectal anastomosis   3) Total abdominal colectomy with end ileostomy   9) N/A 
9. If CD, what type of surgery have been done? 
 1) Resection   2) Fistulectomy and Abscess drainage    9) N/A 
 
